Stock screenerAll disclosures →
EDGAR →
SEPN
Conviction 93HealthcareScan · Mon, Aug 10, 2026Three outside down
SEPN$38.81-0.05%
ResistanceSupportVol 14Insider sell2
3
Vol MA14 279.34K
May 11May 28Jun 16Jul 6Jul 23Aug 10
Price38.81
Change-0.05%
Gap+0.49%
Rel volume1.65×
Avg volume303.55K
Avg $ vol10.72M
SMA 2035.04
SMA 5034.38
SMA 20027.72
Price vs 50+12.88%
Price vs 200+39.99%
MA stackbullish
50/200 cross—
Supertrendup · 32.66
RSI (14)63
MACD hist0.52
MACD crossbull · 5d
Stoch %K / %D77 / 81
ADX (14)22
+DI / −DI23 / 11
RSI divergence—
MACD divergence—
ATR %+5.72%
ADR %6.35%
52w high39.53
52w low10.93
From 52w high-1.82%
Above 52w low+255.08%
New 52w highNo
SqueezeOff
Bollinger width27.59%
%B0.89
Donchian pos81.78%
Donchian high40.65
Donchian low30.55
AVWAP (52w high)39.05
vs AVWAP high-0.62%
AVWAP (52w low)26.36
vs AVWAP low+47.26%
OBV trendFlat
Chaikin MF (20)-0.07
Today vs 20d1.65×
Avg vol (14d)279.34K
Avg vol (20d)303.55K
Avg $ vol (20d)10.72M
Market cap1.81B
RS 3m (vs SPY)+56.23%
RS 6m (vs SPY)+44.76%
RS line new highNo
Trend template8/8
Technical rank87.9
1 week+10.95%
1 month+8.02%
3 months+62.59%
6 months+52.74%
1 year+231.71%
YTD+38.71%
P/E-37.06
P/B4.68
P/S39.42
P/FCF16.52
EPS-1.10
Div yield—
ROE-12.64%
ROA-8.62%
Debt/Eq—
Current4.99
EV/EBITDA-25.89
Gross margin—
Net margin-106.37%
Rev growth4174.51%
EPS growth31.92%
Price target48.17
Target upside24.12%
Analyst ratingBuy
Institutional105.58%
Ent. value1.73B
Revenue26.75M
Net income-13.03M
Gross profit—
Free cash flow109.67M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out45.08M
Employees130
ListedFri, Oct 25, 2024
Free float26.58M
Float %59.2%
Short interest3.35M
Days to cover5.7d
Short volume47.6%
Squeeze score65 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.19 vs −$0.51
Last surprise+62.8% beat
Setup gradeA+
Conviction93 / 100
Pattern quality—
Tech rank87.9 / 100
Group rank86 / 100 · Leading
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmThree outside down
News sentiment—
Financials as of Tue, Jun 30, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in SEPN
No recent disclosed trades by Congress in SEPN. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in SEPN · 3 buys · 7 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Long Daniel D. SVP, Drug Discovery · Stock Option (Right to Buy) · 2026-08-03 | Exercise | 1.82K | — | 2026-08-03 | 2026-08-05 |
Long Daniel D. SVP, Drug Discovery · Stock Option (Right to Buy) · 2026-08-03 | Exercise | 1.52K | — | 2026-08-03 | 2026-08-05 |
Long Daniel D. SVP, Drug Discovery · Common Stock · 2026-08-03 | Exercise | 1.82K | $5K | 2026-08-03 | 2026-08-05 |
Long Daniel D. SVP, Drug Discovery · Common Stock · 2026-08-03 | Exercise | 1.52K | $4K | 2026-08-03 | 2026-08-05 |
Long Daniel D. SVP, Drug Discovery · Common Stock · 2026-08-03 | Sell | 1K | $34K | 2026-08-03 | 2026-08-05 |
Long Daniel D. SVP, Drug Discovery · Common Stock · 2026-08-03 | Sell | 2.33K | $81K | 2026-08-03 | 2026-08-05 |
Bhatt Elizabeth President and COO · Common Stock · 2026-07-15 | Exercise | 4K | $27K | 2026-07-15 | 2026-07-17 |
Bhatt Elizabeth President and COO · Common Stock · 2026-07-15 | Sell | 4K | $136K | 2026-07-15 | 2026-07-17 |
Bhatt Elizabeth President and COO · Stock Option (Right to Buy) · 2026-07-15 | Exercise | 4K | — | 2026-07-15 | 2026-07-17 |
Shaikhly Samira Chief People Officer · Common Stock · 2026-06-29 | Sell | 2.18K | $77K | 2026-06-29 | 2026-06-30 |
SEC filings
EDGAR filings in SEPN · 6 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.